Positive Top-Line Phase III Data in Type 2 Diabetes Achieved for lixisenatide Once-Daily vs. Exenatide Twice-Daily
Lixisenatide Meets Primary Efficacy Endpoint With Fewer Hypoglycaemias COPENHAGEN, Denmark, February 2, 2011 - Zealand Pharma A/S (NASDAQ OMX: ZEAL), a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.
blinkx Introduces TV API, Opens Online Video Index to Technology Partners Looking to Tap Potential of Connected TV
New Application Programming Interface Enables Partners to Leverage blinkx's Web Video Index to Build New Functionality and Apps for the OTT environment
Climate Policy Initiative Analysis Finds European Power Market Improvements Are Important for Wind Power Expansion
Alternative nodal pricing system can result in savings of at least euro 0.8 to euro 2.0 billion for system operation
Fitness First Australia Implements Oracle Business Intelligence 11g to Drive Energy Efficiency Improvements
Fitness First Australia Reduces Total Energy Consumption and Carbon Emission by 10 Percent, Wins Oracle’s ‘Enable the Eco-Enterprise’ Award